Andreas Maderna

AstraZeneca (United States) — United States

Medicine · Health Sciences

22h-index2.2kcitations104works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(23), Monoclonal and Polyclonal Antibodies Research(17), Boron Compounds in Chemistry(17), Crystallization and Solubility Studies(16), X-ray Diffraction in Crystallography(16)

Publications104 total

Abstract 1158: Preclinical characterization of AZD0516, a novel STEAP2 antibody-drug conjugate (ADC) for the treatment of prostate cancer
Cancer Research·2025
Supplementary Methods from Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature
2023Open Access
Data from Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
2023Open Access
Supplementary Figures S1-S6 from Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature
2023Open Access
Supplementary Figures S1 to S11 from Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
2023Open Access
Supplementary Figures S1-S6 from Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature
2023Open Access
Data from Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature
2023Open Access
Supplementary Figures S1 to S11 from Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
2023Open Access
Data from Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
2023Open Access
Supplementary Methods, Table S1 S2, and Figure Legends from Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
2023Open Access
Supplementary Methods from Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature
2023Open Access
Supplementary Methods, Table S1 S2, and Figure Legends from Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
2023Open Access
Data from Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature
2023Open Access
Supplementary Data from Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia
2023Open Access
Data from Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia
2023Open Access
Supplementary Data from Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia
2023Open Access
Data from Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia
2023Open Access
Data from RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer
2023Open Access
Data from RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer
2023Open Access
Supplementary Figure 1 from RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Christopher J. O’Donnell(14), M. Frederick Hawthorne(13), Frank Loganzo(13), Hans‐Peter Gerber(10), Manoj B. Charati(9), Carolyn B. Knobler(9), Walter Siebert(9), Russell G. Dushin(9), Hans Pritzkow(8), Lioudmila Tchistiakova(8), Xingzhi Tan(7), Sylvia Musto(7), My‐Hanh Lam(7), Mauricio Leal(7), Puja Sapra(7), Judy Lucas(6), Andreas Giannakou(6), Nicole Piche‐Nicholas(5), Jennifer Kahler(5), Stéphane Thibault(5)